Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Conditions
Multiple Myeloma · Plasma Cell Disorder
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Norton Healthcare, Inc., Louisville, Kentucky, United States
Nebraska Cancer Institute, Omaha, Nebraska, United States
Mount Sinai, The Tisch Cancer Instutute, New York, New York, United States
MD Anderson Cancer Center, Houston, Texas, United States
Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie, Berlin, Germany
Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III, Chemnitz, Germany
Universitätsklinikum Köln, Cologne, Germany
Asklepios Klinik Altona, Haematologie und internistische Onkologie, Hamburg, Germany
Universitätsklinikum Heidelberg, Heidelberg, Germany
Universitätsklinikum Schleswig-Holstein, Kiel, Germany
UKSH Campus Lübeck Klinik für Hämatologie und Onkologie, Lübeck, Germany
Universitätsklinikum Mainz, Mainz, Germany
Semmelweis University, Belgyogyaszati es Onkologiai Klinika, Budapest, Hungary
National Institute of Oncology, Department of Oncological Internal Medicine, Budapest, Hungary
Pécsi Tudományegyetem Klinikai Központ, Pécs, Hungary
Pratia Onkologia Katowice, Katowice, Poland
Pratia Onkologia Kraków, Krakow, Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland
Szpital Wojewodzki w Opolu, Opole, Poland
AIDPORT Sp. zo.o., Skórzewo, Poland
MICS Centrum Medyczne Torun, Torun, Poland
Arensia Clinics SRL, Bucharest, Romania
Oncology Institute Prof. Dr. Ion Chiricuta I.O.C.N., Cluj-Napoca, Romania